Overview
68Ga-grazytracer PET/CT in Subjects With Non-small Cell Lung Cancer or Melanoma
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2023-08-31
2023-08-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-grazytracer in subjects with non-small cell lung cancer or melanoma receiving immune checkpoint inhibitors (e.g., Ipilimumab, Nivolumab). A single dose of 2.96 MBq/kg body weight of 68Ga-grazytracer will be injected intravenously. The visual and semiquantitative methods will be used to assess the PET/CT images.Phase:
Early Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Beijing Cancer HospitalCollaborator:
Peking University Health Science Center
Criteria
Inclusion Criteria:1. 18-75 years old;
2. ECOG score 0 or 1 point;
3. Participants with suspected or confirmed non-small cell lung cancer or melanoma who
are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or
staging.
Exclusion Criteria:
1. Pregnant or nursing;
2. Severe hepatic or renal dysfunction;
3. Low WBC (less than 3 x 10^9/L);
4. Unable to comply with the PET/CT imaging procedures.